<DOC>
	<DOC>NCT01368185</DOC>
	<brief_summary>This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.</brief_summary>
	<brief_title>Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Inclusion criteria: Participant was &gt;20 years and &lt;75 years of age on the index date (i.e., the date of initiating MK0954A therapy) Diagnosed with hypertension and had received MK0954A 50/12.5 mg for at least 3 months Had at least one serum uric acid measurements at baseline and one at 3 months after using MK0954A 50/12.5 mg Had the following records documented in the chart during the data collection period: medical history and comorbidities (if available) sitting blood pressure, serum uric acid, lipid profile test results before and after using MK0954A 50/12.5 mg serum electrolytes, serum creatinine, and premeal sugar (if available) prescription information of all antihypertensive regimens Exclusion criteria: Had been treated with diuretic or angiotensinreceptor blockers (ARBs) 2 weeks before initiated treatment with MK0954A 50/12.5 mg Serum creatinine &gt;2 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Essential hypertension Uric acid Retrospective Hyzaar</keyword>
</DOC>